Poorly Differentiated Neuroendocrine Carcinoma of the Small Intestine: Understanding Your Pathology Report

Section Editor: David Driman MBChB FRCPC
November 16, 2026


Print this article

Poorly differentiated neuroendocrine carcinoma of the small intestine is a rare, fast-growing cancer. It starts from cells in the lining of the small intestine that have features of neuroendocrine cells, which are cells that make hormones. This cancer can start anywhere in the small intestine, including the duodenum, jejunum, and ileum. It can also start in the ampulla, where the bile duct and pancreatic duct drain into the duodenum. Your report may call it a neuroendocrine carcinoma, NEC, small cell neuroendocrine carcinoma, or large cell neuroendocrine carcinoma.

This cancer is not the same as a well-differentiated neuroendocrine tumor, which is much more common and usually grows slowly. This article explains how doctors diagnose and stage poorly differentiated neuroendocrine carcinoma of the small intestine, and what the other findings in your pathology report mean.

Who gets poorly differentiated neuroendocrine carcinoma of the small intestine?

Poorly differentiated neuroendocrine carcinoma of the small intestine is uncommon. Most neuroendocrine growths in the small intestine are well-differentiated neuroendocrine tumors, and only a small number are carcinomas. This cancer is found mostly in adults. Because it is so rare, reliable figures for age and sex for this site alone are limited.

What causes poorly differentiated neuroendocrine carcinoma of the small intestine?

The cause of poorly differentiated neuroendocrine carcinoma of the small intestine is usually not known. The cancer cells carry changes, called mutations, in genes that normally control cell growth. The most common change is in the gene TP53, which normally acts as a brake on cell division. Loss of another brake gene, RB1, is also frequent.

Some of these cancers develop next to an adenocarcinoma or a precancerous growth called an adenoma. This suggests that, in some people, the cancer starts from cells that first formed a glandular growth. A small number of these cancers are linked to an inherited condition called Lynch syndrome (see the biomarker section below).

What are the symptoms of poorly differentiated neuroendocrine carcinoma of the small intestine?

The symptoms of poorly differentiated neuroendocrine carcinoma of the small intestine depend on where the tumor starts and how far it has spread. Most people are diagnosed after the cancer has already spread. Symptoms can include the following.

  • Pain and weight loss. Abdominal pain, loss of appetite, and weight loss are common.
  • Bleeding and anemia. The tumor can bleed into the bowel, causing black stools or a low red blood cell count.
  • Blockage. A tumor in the jejunum or ileum can block the bowel and cause cramping, bloating, and vomiting.
  • Jaundice. A tumor in the duodenum near the ampulla can block the bile duct, causing yellowing of the skin and eyes.
  • Symptoms of spread. Spread to the liver can cause pain under the right ribs or abdominal swelling.

How is the diagnosis made?

The diagnosis of poorly differentiated neuroendocrine carcinoma of the small intestine is made when a pathologist examines tissue from the tumor under a microscope. Tumors in the duodenum and ampulla are usually sampled with a biopsy during an upper endoscopy, in which a thin camera is passed through the mouth into the duodenum. Tumors in the jejunum and ileum are harder to reach, so the diagnosis is often made after surgery or from a needle biopsy of a tumor in the liver.

Under the microscope, the cancer cells grow in solid sheets and nests and divide very quickly. Large areas of dead tumor, called necrosis, are common. The pathologist uses special tests to confirm that the cells are neuroendocrine and to measure how fast they are dividing, as described in the next section.

Once the diagnosis is confirmed, imaging is used to find out how far the cancer has spread. This usually includes a CT scan of the chest, abdomen, and pelvis, and sometimes an MRI or a PET scan.

Immunohistochemistry

Pathologists use immunohistochemistry to confirm poorly differentiated neuroendocrine carcinoma of the small intestine. This test uses antibodies to show which proteins the cancer cells make. Your report may list the following results.

  • Synaptophysin. Synaptophysin is a protein found in neuroendocrine cells. It is positive in most of these cancers and is one of the main tests used to confirm the diagnosis.
  • Chromogranin. Chromogranin is another neuroendocrine protein. In this cancer, it may be weak, patchy, or negative, especially in small cell neuroendocrine carcinoma.
  • INSM1. INSM1 is a protein found in the nucleus of neuroendocrine cells. A positive result supports the diagnosis.
  • Keratins. Keratins are proteins found in carcinomas. A positive result shows the tumor is a carcinoma rather than a lymphoma or another type of cancer.
  • Ki-67. Ki-67 shows the percentage of cancer cells that are dividing. In neuroendocrine carcinoma, the Ki-67 index is always above 20% and is usually much higher, often above 55%.
  • p53 and Rb. Abnormal p53 staining or loss of the Rb protein is common in neuroendocrine carcinoma. These results help distinguish it from a fast-growing, grade 3, well-differentiated neuroendocrine tumor, which is treated differently.

Not every case needs every stain. Your pathologist chooses the tests needed to answer the questions raised by your tumor.

What are the different types of poorly differentiated neuroendocrine carcinoma?

The WHO classification of digestive system tumors (5th edition, 2019) divides this cancer into two types. The types are based on how the cells look under the microscope. Both types are treated similarly.

  • Small cell neuroendocrine carcinoma. The cancer cells are small, with very little cytoplasm and dark, tightly packed nuclei. They look like the cells of small cell carcinoma of the lung.
  • Large cell neuroendocrine carcinoma. The cancer cells are larger, with more cytoplasm and a visible nucleolus. They often form nests and rosettes.

If the pathologist cannot tell which type is present, the report may say “neuroendocrine carcinoma (poorly differentiated)” without naming a type. Sometimes a neuroendocrine carcinoma is mixed with another type of cancer, such as adenocarcinoma. When each part makes up at least 30% of the tumor, the diagnosis is a mixed neuroendocrine-non-neuroendocrine neoplasm, or MiNEN. Your report will then describe each part of the tumor.

Histologic grade

Poorly differentiated neuroendocrine carcinoma of the small intestine is a high-grade cancer by definition. Grade describes how different the cancer cells look from normal cells and how fast they divide. In this cancer, the pathologist sees more than 20 dividing cells (mitotic figures) in an area of 2 square millimeters, and the Ki-67 index is above 20%.

Because this cancer is always high grade, the grade does not vary from one patient to another. Some reports do not list a separate grade. Others list it as G3, or as G4 for small cell neuroendocrine carcinoma, using the CAP protocol categories. The high grade helps predict how the cancer will behave and guides treatment decisions, which are usually similar to those for small cell carcinoma of the lung.

Depth of invasion

Poorly differentiated neuroendocrine carcinoma of the small intestine starts in the inner lining and can grow deeper into the bowel wall. The pathologist describes how deep the cancer has grown, because this sets the tumor stage (pT). The wall of the small intestine has the following layers, from the inside out.

  • Mucosa. The inner lining, including a thin layer of supporting tissue called the lamina propria.
  • Submucosa. The submucosa is a connective tissue layer with blood vessels and lymphatic channels.
  • Muscularis propria. The muscularis propria is the thick muscle layer that moves food along the bowel.
  • Subserosa and serosa. The subserosa is a thin layer of tissue outside the muscle. The serosa is the smooth outer covering of the bowel.

For tumors of the ampulla, the report also says whether the cancer has grown beyond the sphincter of Oddi, a ring of muscle around the ampulla. It also says whether the cancer has grown into the pancreas.

Perineural invasion

Perineural invasion means cancer cells are found along or around a nerve. In poorly differentiated neuroendocrine carcinoma of the small intestine, perineural invasion is reported as not identified, present, or cannot be determined. When present, it shows that the cancer can travel along nerves into nearby tissue.

Lymphovascular invasion

Lymphovascular invasion means cancer cells are seen inside a blood vessel or a lymphatic channel. In poorly differentiated neuroendocrine carcinoma of the small intestine, lymphovascular invasion is reported as not identified, present, or cannot be determined. When present, it shows that cancer cells can spread to lymph nodes, the liver, and other organs.

Surgical margins

When poorly differentiated neuroendocrine carcinoma of the small intestine is removed by surgery, the pathologist checks the margins. A margin is the cut edge of the tissue. The margins examined depend on the operation. For a segment of jejunum or ileum, they include the two cut ends of the bowel and the mesenteric margin. The mesenteric margin is the edge of the fatty tissue that holds the bowel in place. For a Whipple operation, they also include the bile duct, the pancreas, and the tissue next to the main blood vessels.

  • Negative margin. No cancer cells are seen at the cut edge. This suggests the tumor was completely removed. The report may also give the distance from the cancer to the closest margin.
  • Positive margin. Cancer cells are seen at the cut edge. For the mesenteric margin and the margin next to the main blood vessels, cancer within 1 mm of the edge is also reported as positive. A positive margin increases the risk that the cancer will come back in the same place, and may lead the care team to consider further treatment.

Lymph nodes

Lymph nodes are small immune organs that filter fluid from the bowel. Poorly differentiated neuroendocrine carcinoma of the small intestine often spreads to the lymph nodes in the mesentery or near the pancreas. During surgery, these lymph nodes are removed and examined under the microscope.

The report gives the total number of lymph nodes examined and how many contain cancer. The number of positive lymph nodes sets the nodal stage (pN). The report may also say whether there is extranodal extension. This means cancer cells have broken through the outer capsule of a lymph node into the surrounding tissue.

Biomarker and molecular testing

Biomarker testing in poorly differentiated neuroendocrine carcinoma of the small intestine looks for changes linked to specific treatments. It is most often done when the cancer is advanced or has spread. The ENETS 2023 guidance encourages molecular testing for these cancers. Most tumors will not have a change that leads to a targeted treatment, but a small number will.

Mismatch repair (MMR) and microsatellite instability (MSI)

Mismatch repair proteins fix mistakes that happen when a cell copies its DNA. The four proteins are MLH1, PMS2, MSH2, and MSH6. When one is lost, mistakes build up in the DNA, creating a pattern called microsatellite instability (MSI). About 4 in 100 high-grade neuroendocrine cancers of the digestive system are MSI-high.

Testing is done with immunohistochemistry for the four proteins, or with a DNA test for MSI. Results are reported as follows.

  • MMR proficient, or “intact,” “retained,” or “no loss of expression.” All four proteins are present. The mismatch repair system is working normally. This is the most common result.
  • MMR deficient (dMMR), or “loss of expression.” One or more proteins are missing. This result is usually paired with MSI-high.
  • MSI-stable (MSS) or MSI-high (MSI-H). These are the results of the DNA test. MSI-stable matches a proficient result, and MSI-high matches a deficient result.

A deficient or MSI-high result matters for two reasons. First, pembrolizumab, an immunotherapy drug, is approved by the FDA (2017) and Health Canada for unresectable or metastatic MMR-deficient or MSI-high solid tumors that have grown after earlier treatment. Second, the result may point to Lynch syndrome, an inherited condition that raises the risk of several cancers. When MLH1 and PMS2 are lost, testing for MLH1 promoter methylation can help show whether the change is inherited. Genetic counseling may be offered.

BRAF V600E

BRAF is a gene that helps control cell growth. A specific change called V600E keeps the growth signal switched on. This change is found in a small number of neuroendocrine carcinomas of the digestive system. The test is usually done by DNA sequencing.

  • BRAF V600E not detected (wild type). The change was not found. This is the usual result.
  • BRAF V600E detected. The change is present. Dabrafenib combined with trametinib received accelerated approval from the FDA in 2022 for solid tumors with this change that have grown after earlier treatment.

NTRK gene fusions

An NTRK gene fusion happens when part of an NTRK gene joins with another gene, creating a protein that drives growth. These fusions are very rare in this cancer. They are found by DNA or RNA sequencing.

  • No NTRK fusion detected. This is the expected result.
  • NTRK fusion detected. Larotrectinib and entrectinib are authorized by Health Canada, with conditions, for solid tumors with an NTRK fusion. A positive result makes these drugs an option the care team can discuss.

Tumor mutational burden (TMB)

Tumor mutational burden is the number of gene changes in the cancer cells, measured in mutations per megabase (mut/Mb) by next-generation sequencing. In one large study, about 7 in 100 high-grade neuroendocrine cancers of the digestive system were TMB-high.

  • TMB-low. Fewer than 10 mut/Mb. This is the most common result.
  • TMB-high. 10 or more mut/Mb. Pembrolizumab received accelerated approval from the FDA in 2020 for TMB-high solid tumors that have grown after earlier treatment.

Learn more about these tests in our Biomarkers section.

Pathologic stage (pTNM)

Poorly differentiated neuroendocrine carcinoma of the small intestine is staged using the AJCC Cancer Staging Manual, 8th edition, as used in current CAP protocols. The stage combines the tumor stage (pT) and nodal stage (pN). The metastatic stage (M) describes spread to distant organs and is usually determined by imaging rather than by the pathologist. The pT and pN categories differ for the ampulla, so both sets are given below.

Tumor stage (pT): duodenum, jejunum, and ileum

  • pT1a. The cancer has grown into the lamina propria.
  • pT1b. The cancer has grown into the submucosa.
  • pT2. The cancer has grown into the muscularis propria.
  • pT3. The cancer has grown through the muscularis propria into the tissue just outside it, without breaking through the serosa.
  • pT4. The cancer has broken through the serosa, or has grown into nearby organs or structures. For tumors of the duodenum, this includes the pancreas or bile duct.

Tumor stage (pT): ampulla

  • pT1a. The cancer is limited to the ampulla or the sphincter of Oddi.
  • pT1b. The cancer has grown beyond the sphincter of Oddi or into the duodenal submucosa.
  • pT2. The cancer has grown into the muscularis propria of the duodenum.
  • pT3a. The cancer has grown 0.5 cm or less into the pancreas.
  • pT3b. The cancer has grown more than 0.5 cm into the pancreas, or into the fat around the pancreas or duodenum.
  • pT4. The cancer involves the large arteries near the pancreas: the celiac axis, superior mesenteric artery, or common hepatic artery.

Nodal stage (pN)

  • pN0. No cancer cells were found in any lymph node examined.
  • pN1. For the duodenum, jejunum, and ileum, cancer cells were found in one or two lymph nodes. For the ampulla, cancer cells were found in one to three lymph nodes.
  • pN2. For the duodenum, jejunum, and ileum, cancer cells were found in three or more lymph nodes. For the ampulla, cancer cells were found in four or more lymph nodes.
  • pNX. The lymph nodes could not be assessed, for example because none were removed.

Cancer in lymph nodes farther away, such as those near the aorta, is counted as distant spread (M1) rather than as nodal disease.

What is the prognosis?

The prognosis for poorly differentiated neuroendocrine carcinoma of the small intestine is generally poor, because the cancer grows quickly and is usually found after it has spread. According to the ENETS 2023 guidance, the median survival for people with neuroendocrine carcinoma of the digestive system that has spread is 11 to 12 months. This means half of patients live longer than that, and half do not.

The outlook is better when the cancer is found before it has spread. Some people whose cancer is completely removed by surgery are cured. However, the cancer often comes back after surgery, so follow-up is close. Pathologic features associated with a worse outcome include the following.

  • Spread to distant organs. Spread to the liver or other organs at diagnosis is the strongest predictor of a poor outcome.
  • Lymph node spread. Cancer in more lymph nodes (a higher pN) is linked to a higher risk of the cancer coming back.
  • Deep invasion. A higher pT, especially growth through the serosa or into nearby organs, is linked to a worse outcome.
  • Positive margin. Cancer at the cut edge increases the risk of the cancer coming back in the same place.

A small group of MSI-high neuroendocrine carcinomas of the digestive system appears to have a better outlook than expected.

What happens after the diagnosis?

After poorly differentiated neuroendocrine carcinoma of the small intestine is confirmed, the next steps depend on how far the cancer has spread. Imaging and the stage, margins, and lymph nodes in the pathology report show this. A team that includes a medical oncologist, a surgeon, a gastroenterologist, and a radiation oncologist usually plans care.

  • Localized cancer. When imaging shows the cancer has not spread to distant organs, the ENETS 2023 guidance states that surgery may be of benefit. The operation depends on where the tumor is. A Whipple operation may be needed for a tumor in the duodenum or ampulla. Because the cancer often comes back, the care team may also discuss chemotherapy.
  • Advanced or metastatic cancer. When the cancer has spread, chemotherapy is the main treatment. The ENETS 2023 guidance recommends carboplatin combined with etoposide as first-line treatment. If the cancer grows despite this, irinotecan combined with a fluoropyrimidine has the best evidence as second-line treatment.
  • Biomarker results. An MMR-deficient, MSI-high, TMB-high, BRAF V600E, or NTRK fusion result may make immunotherapy or a targeted drug an option to discuss with your care team.
  • Clinical trials. Because few treatments are available for this rare cancer, your oncologist can tell you whether a clinical trial is open to you.
  • Follow-up. Regular imaging is used to watch for the cancer coming back or growing.

If the biomarker tests suggest Lynch syndrome, you may be referred for genetic counseling, which can also help your family members.

Questions to ask your doctor

  • In which part of my small intestine did the cancer start?
  • Is my cancer a small cell or a large cell neuroendocrine carcinoma?
  • Was any adenocarcinoma found with it, and is it a MiNEN?
  • What was the Ki-67 index?
  • Were the p53 or Rb stains abnormal?
  • Has the cancer spread to my lymph nodes, liver, or other organs?
  • What is the pathologic stage (pT and pN)?
  • Were the surgical margins negative?
  • Was lymphovascular or perineural invasion found?
  • Was my tumor tested for mismatch repair or MSI?
  • Will my tumor be tested with next-generation sequencing for BRAF, NTRK, or TMB?
  • Is surgery an option for me, or is chemotherapy the first step?
  • Is there a clinical trial I could join?
  • Should I see a genetic counselor?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?